Global Bladder Cancer Market Research and Forecast 2018-2023

  • ID: 4471505
  • Report
  • Region: Global
  • Orion Market Research Private Limited
15 % OFF
until Sep 30th 2018
1 of 4

FEATURED COMPANIES

  • Astrazeneca Plc
  • Celgene Corporation
  • Emd Serono, Inc
  • Epocrates, Inc.
  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • MORE
Bladder cancer is a tumour, which starts in the cells of the bladder. Factors such as increasing incidence of bladder cancer fuel the growth of the market. As per American Medical Association, a growth of 31% in global bladder cancer has been recorded in 2015 as compared to 2005 Furthermore, rise in awareness about cancer and their available therapies, increasing healthcare expenditure, growing smoking and tobacco consumption are also motivating the market.

Sometimes, bladder cancer is asymptomatic in nature, due to which patients can’t get diagnosed in the due course of time. It is the major restrain for the market. Cisplatin is a generic drug available for the treatment of bladder cancer. It is being manufactured all across the globe. Besides that, various companies are getting FDA approval of new drugs for bladder cancer and numerous drugs are being sent for clinical trials. Hence, innovation in drug development, subsequent technological advancements, and pipeline products are expected to find immense opportunity during the forecast period.

The global bladder cancer market is analysed on the basis of geographical regions that are contributing significantly towards the growth of the market. The market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to dominate in the global bladder cancer market owing to high prevalence of bladder cancer in the US. The major factors that are augmenting the market are high prevalence of bladder cancer diseases, high healthcare expenditure, and government policies. Asia Pacific region is expected to have a considerable market growth during the forecast period. Major countries contributing in the region are India, China, and Japan. Large patients base, continuous increment in economy &healthcare facilities are the major factors for the growth of the market in the region.

The major companies active in the market are AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Epocrates, Genentech, GlaxoSmithKline, Roche, Merck & Co, Novartis, Pfizer and so on. These companies are focusing on product innovations, expansions, finding new markets or innovating their core competency to expand their individual market share. The report includes detailed insights into market overview, strategic recommendations, key company analysis, key findings, analyst insights, market determinants, market segmentation and company profiling of the market.

Market Segmentation:

Global Bladder Cancer market is segmented on the basis of regional outlook and following segments:
  • Global Bladder Cancer Market Research and Analysis, By Cancer Type
  • Global Bladder Cancer Market Research and Analysis, By Diagnosis
  • Global Bladder Cancer Market Research and Analysis, By Therapy
  • Global Bladder Cancer Market Research and Analysis, By Region
The Report covers:
  • Comprehensive research methodology of Global Bladder Cancer Market.
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the
  • Global Bladder Cancer Market.
  • Insights about market determinants which are stimulating the Global Bladder Cancer Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astrazeneca Plc
  • Celgene Corporation
  • Emd Serono, Inc
  • Epocrates, Inc.
  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. by Segments
1.2.2. by Geography
1.2.3. by Stakeholders
1.2.4. Exceptions

2. Market Overview and Insights
2.1. Definition
2.2. Patent Analysis
2.3. Analyst Insights & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendation
2.3.3. Conclusion
2.4. Regulation
2.4.1.1. United States
2.4.1.2. European Union
2.4.1.3. China
2.4.1.4. India

3. Market Determinant
3.1. Motivators
3.1.1. Rise in Awareness About Cancer Diseases and Their Available Therapies
3.1.2. Increasing Healthcare Expenditure
3.1.3. Increasing Incidence of Bladder Cancer
3.1.4. Growing Smoking and Tabaco Consumption
3.1.5. High Prevalence in Geriatric Population & Increasing Geriatric Population Base
3.2. Restraints
3.2.1. Asymptomatic Nature of the Disease
3.3. Opportunities
3.3.1. Innovation in Drug Development, and Subsequent Technological Advancements & Pipeline Product

4. Market Segmentation
4.1. Global Bladder Cancer Market, by Cancer Type
4.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
4.1.2. Squamous Cell Bladder Cancer
4.1.3. Adenocarcinoma
4.1.4. Other Rare Types (Sarcomas, Carcinoma in Situ)
4.2. Global Bladder Cancer Market, by Diagnosis Method
4.2.1. Cystoscopy
4.2.2. Biopsy
4.2.3. Urinalysis
4.2.4. Urine Cytology
4.2.5. Intravenous Pyelogram (Ivp)
4.2.6. Other
4.3. Global Bladder Cancer Market, by Therapy
4.3.1. Chemotherapy
4.3.2. Immunotherapy
4.3.3. Radiation Therapy
4.3.4. Surgery
4.3.5. Other (Pd-1 Modulators, Radical Cystectomy, Clinical Trial, Intravesical Therapy)

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.3. APAC
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of APAC
6.4. Rest of the World

7. Company Profiles
7.1. Astrazeneca PLC
7.2. Bristol-Myers Squibb
7.3. Celgene Corporation
7.4. Eli Lilly and Co
7.5. Emd Serono, Inc
7.6. Endo International PLC
7.7. Epocrates, Inc.
7.8. Genentech, Inc
7.9. Glaxosmithkline PLC
7.10. Hoffmann-La Roche Ag
7.11. Merck & Co., Inc.
7.12. Novartis International Ag
7.13. Nucleix Ltd
7.14. Pfizer Inc
7.15. Taris Biomedical Llc
7.16. Spectrum Pharmaceuticals, Inc

List of Tables:
Table 1 Global Bladder Cancer Market, by Cancer Type, 2017-2023 ($ Million)
Table 2 Transitional Cell Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Table 3 Squamous Cell Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Table 4 Adenocarcinoma Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Table 5 Other Rare Types Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Table 6 Global Bladder Cancer Market Research and Analysis, by Therapy 2017-2023 ($ Million)
Table 7 Chemotherapy Market Research and Analysis, 2017-2023 ($ Million)
Table 8 Immunotherapy Market Research and Analysis, 2017-2023 ($ Million)
Table 9 Radiation Therapy Market Research and Analysis, 2017-2023 ($ Million)
Table 10 Surgery Market Research and Analysis, 2017-2023 ($ Million)
Table 11 Other Therapeutics Market Research and Analysis, 2017-2023 ($ Million)
Table 12 Global Bladder Cancer Market Research and Analysis, by Diagnosis Method 2017-2023 ($ Million)
Table 13 Cystoscopy Bladder Cancer Diagnostic Market Research and Analysis, 2017-2023 ($ Million)
Table 14 Biopsy Bladder Cancer Diagnostic Market Research and Analysis, 2017-2023 ($ Million)
Table 15 Urinalysis Bladder Cancer Diagnostic Market Research and Analysis, 2017-2023 ($ Million)
Table 16 Urine Cytology Bladder Cancer Diagnostic Market Research and Analysis, 2017-2023 ($ Million)
Table 17 Intravenous Pyelogram Bladder Cancer Diagnostic Market Research and Analysis, 2017-2023 ($ Million)
Table 18 North America Bladder Cancer Market Research and Analysis, by Cancer Type, 2017-2023 ($ Million)
Table 19 North America Bladder Cancer Market Research and Analysis, by Diagnosis Method 2017-2023 ($ Million)
Table 20 North America Bladder Cancer Market Research and Analysis, by Therapy Method 2017-2023 ($ Million)
Table 21 North America Bladder Cancer Market Research and Analysis, by Countries 2017-2023 ($ Million)
Table 22 Europe Bladder Cancer Market Research and Analysis, by Cancer Type, 2017-2023 ($ Million)
Table 23 Europe Bladder Cancer Market Research and Analysis, by Diagnosis Method 2017-2023 ($ Million)
Table 24 Europe Bladder Cancer Market Research and Analysis, by Therapy Method 2017-2023 ($ Million)
Table 25 Europe Bladder Cancer Market Research and Analysis, by Countries 2017-2023 ($ Million)
Table 26 Asia Pacific Bladder Cancer Market Research and Analysis, by Cancer Type, 2017-2023 ($ Million)
Table 27 Asia Pacific Bladder Cancer Market Research and Analysis, by Diagnosis Method 2017-2023 ($ Million)
Table 28 Asia Pacific Bladder Cancer Market Research and Analysis, by Therapy Method 2017-2023 ($ Million)
Table 29 Asia Pacific Bladder Cancer Market Research and Analysis, by Countries 2017-2023 ($ Million)

List of Figures:
Figure 1 Global Bladder Cancer Market Share, by Cancer Type, 2017 and 2023 (%)
Figure 2 Global Bladder Cancer Market Share, by Diagnostic Method 2017 and 2023 (%)
Figure 3 Global Bladder Cancer Market Share, by Therapy 2017 and 2023 (%)
Figure 4 Global Bladder Cancer Market Share, by Geography, 2017 and 2023 (%)
Figure 5 North America Bladder Cancer Market Size, 2017-2023($ Million)
Figure 6 United States Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 7 Canada Market Bladder Cancer Research and Analysis, 2017-2023 ($ Million)
Figure 8 Europe Market Research and Analysis, 2017-2023($ Million)
Figure 9 UK Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 10 Germany Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 11 Spain Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 12 France Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 13 Italy Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 14 ROE Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 15 Asia Pacific Market Research and Analysis, 2017-2023($ Million)
Figure 16 China Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 17 India Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 18 Japan Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 19 Rest of Asia Pacific (RoAPAC) Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Figure 20 Rest of World (Row) Bladder Cancer Market Research and Analysis, 2017-2023 ($ Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astrazeneca Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly And Co
  • Emd Serono, Inc
  • Endo International Plc
  • Epocrates, Inc.
  • Genentech, Inc
  • Glaxosmithkline Plc
  • Hoffmann-La Roche Ag
  • Merck & Co., Inc.
  • Novartis International Ag
  • Nucleix Ltd
  • Pfizer Inc
  • Taris Biomedical Llc
  • Spectrum Pharmaceuticals, Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll